

## CancerLinQ® helps practices and researchers transform patient care through quality automation tools, actionable insights, and de-identified research data sets.

CancerLinQ aggregates de-identified, real-world data representing over 5 million patients and is the only oncology platform in the world backed by the expertise of American Society of Clinical Oncology (ASCO) members. The CancerLinQ database is among the largest in oncology and reflects the real world of cancer care with ever-increasing diversity in geography, practice settings, patient demographics, and cancer types.

### How does CancerLinQ benefit physicians, patients, and the cancer-care community?

#### **CancerLinQ Platform**

SmartLinQ™ and CancerLinQ Insights enable oncology practice administrators, quality managers, physicians, and care teams to use near real-time data to:

- Measure and improve care using ASCO's internationally recognized Quality Oncology Practice Initiative (QOPI®) measures
- Pinpoint opportunities for clinical quality improvement
- Benchmark quality performance against the CancerLinQ network
- Automate quality management and reporting to quality programs like the QOPI Certification Program, LLC, a wholly owned subsidiary of the Association for Clinical Oncology
- Identify opportunities to improve data capture to improve quality measurement capabilities
- View population health data and trends to help improve patient care and practice operations
- Explore the experiences of patients across the entire CancerLinQ network with access to de-identified, real-world data representing over 5 million patients

#### **CancerLinQ Discovery®**

CancerLinQ Discovery, a fully de-identified, secondary real-world research database, includes longitudinal patient data from multiple clinical settings, including urban and rural community practices, academic hospitals, and major health systems. **CancerLinQ Discovery:**

- Enables researchers to generate real-world evidence using one of the largest and most diverse data sets in oncology
- Makes de-identified, real-world data available to academic researchers, non-profit organizations, health care companies, providers, government agencies, and others working to improve patient care through analysis of real-world data
- Provides aggregated, de-identified data sets that can reveal insights about oncology practices across the spectrum of care, unrecognized drug toxicities, off-label use, and more

CancerLinQ's products and services reflect a deep understanding of the needs of oncologists, cancer centers, and researchers. Fluent in both the language of oncology and technology, and a trusted partner to over 100 cancer centers and community oncology practices, CancerLinQ is uniquely positioned to advance cancer care and research.

For more information or to schedule a demonstration, email [info@cancerlinq.org](mailto:info@cancerlinq.org).

**CancerLinQ.org**

## Frequently Asked Questions

### How can my practice participate in CancerLinQ®?

Any practice that utilizes an electronic health record (EHR) system and has at least one ASCO member is eligible for participation (CancerLinQ can connect with a wide variety of EHR systems). The decision to participate in CancerLinQ is made at the practice level rather than by an individual clinician. To schedule an introductory presentation or demonstration of the platform, please contact [info@cancerlinq.org](mailto:info@cancerlinq.org) and we will be happy to discuss how your practice can participate.

### What is the fee to participate in CancerLinQ?

Fees for participation in CancerLinQ follow a typical software as a service (SaaS) model with an activation fee and annual subscriber fees for access to the CancerLinQ platform. CancerLinQ Discovery® fees are separate. Contact us at [info@cancerlinq.org](mailto:info@cancerlinq.org) to learn more.

### How long does the activation process take?

CancerLinQ LLC strives to ensure the activation process has minimal impact on participating practices. The CancerLinQ team performs the majority of onboarding work on the subscriber's behalf, which is tailored to your practice based on your EHR. The onboarding period varies depending on the data-retrieval method used but usually takes between 60 and 90 days from when data is received. The expected time commitment for participating practices during that period is 1–2 hours per week via telephone.

### Is CancerLinQ HIPAA compliant?

Yes, CancerLinQ is a Business Associate to participating practices under the Health Insurance Portability and Accountability Act (HIPAA). CancerLinQ's HIPAA compliance program is implemented with a dedicated staff, as well as CancerLinQ's privacy and security officer, to oversee its compliance. This staff supports CancerLinQ to implement industry-standard safeguards, conduct due diligence on vendors, and monitor and enforce policies and protocols related to HIPAA compliance. HIPAA training is required for all CancerLinQ staff and contractors prior to accessing identifiable information.

### Who has access to my practice's data?

CancerLinQ's systems and processes ensure that protected health information (PHI) is securely ingested and protected according to HIPAA requirements. Each practice decides which of its physicians and other personnel will have access to the practice's PHI within the CancerLinQ platform. Select trained staff at CancerLinQ have access to PHI, as do certain personnel from CancerLinQ's curation subcontractors. Others have access only to aggregate, de-identified CancerLinQ data based on the CancerLinQ Data Governance Policies. CancerLinQ's data governance policies and other information about data use are posted publicly on [CancerLinQ.org](http://CancerLinQ.org).

### Is patient consent required for practices to participate?

Because CancerLinQ is providing healthcare operations and quality-improvement services, individual patient consent is not required under HIPAA. CancerLinQ requires practices follow their internal Institutional Review Board processes and state requirements and obtain consent if required. CancerLinQ also requires that practices notify their current patients regarding the practice's participation in CancerLinQ. CancerLinQ strongly recommends practices provide their patients an opportunity to opt out of having their data included in CancerLinQ, should patients wish to. CancerLinQ is set up to accommodate a patient's decision to opt out. If CancerLinQ is informed by a practice that a patient wishes to opt out of participation in CancerLinQ, CancerLinQ will work to have the patient's identifiable data removed from the system going forward.

### What is the advantage of working with ASCO?

CancerLinQ is the only physician-led, big-data initiative in cancer. ASCO launched CancerLinQ with one goal: to rapidly improve the care of cancer patients. CancerLinQ is driven by ASCO's expertise—leveraging the expertise of the world's leading oncologists. CancerLinQ has the trust of the cancer community and is the only big-data effort in cancer driven by a professional society.